Dyax Corp. (DYAX) Appoints Dr. Abbie Celniker To Board Of Directors

5/13/2015 10:59:50 AM

BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced the appointment of Abbie Celniker, Ph.D., to its Board of Directors.

"Abbie brings nearly three decades of business and scientific leadership in the biotechnology and pharmaceutical industries to Dyax, with a proven track record of successfully developing and commercializing life science products," said Henry E. Blair, Chairman of Dyax's Board of Directors.

Suggested Articles

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.

Netherlands-based biotech Vico Therapeutics has signed up biopharma veteran Rupert Sandbrink, M.D., Ph.D., as its new chief medical officer.

French biotech Genfit is cutting its way out of its phase 3 NASH disaster in the summer and cresting two new units.